All In Biotech

Free tool

FAERS Monitor: Andembry

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761367 or its brand name (Andembry, Garadacimab-Gxii). Reports on generic versions are filed under their own applications.

Reports

767

Serious

597

78% of reports

Hospitalization

193

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hereditary angioedema498
  • drug ineffective93
  • product dose omission issue83
  • stress68
  • product use issue60
  • weight decreased48
  • fatigue43
  • therapy interrupted43
  • hospitalisation42
  • insurance issue42
  • weight increased42
  • pain38
  • off label use34
  • headache32
  • illness32

Reports by year received

View as table
YearReports
20214
20223
20235
202425
2025223
2026507

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,392 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hereditary angioedemaSignal4981334.41262.4631,826
insurance issueSignal4275.556.33,008
stressSignal6825.920.61,606
therapy interruptedSignal4316.512.3613
product use issueSignal608.86.9408
illnessSignal328.56.1206
product dose omission issueSignal837.76.3487
hospitalisationSignal427.55.6232
weight increasedSignal425.13.8138
weight decreasedSignal484.73.6139
drug ineffective931.91.644
pain381.71.210
fatigue431.51.17
headache321.41.03
off label use341.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.